Medtronic is partnering with San Mateo, CA-based Nile Therapeutics to develop a new outpatient treatment for sufferers of acutely decompensated heart failure. Financial details of the deal have not been disclosed.
Nile will focus on Phase I and II clinical trials for its proprietary natriuretic peptide, cenderitide, using Medtronic's diabetes pump technology, knowledge and cash flow. The first trial should be completed by the first quarter of 2012. According to the release, the Phase I trial will study the effects of cenderitide on heart failure patients when it is administered for 24 hours via a continuous subcutaneous drip.
"This collaboration will be an important step on our path to developing cenderitide as a potential new therapy for patients with cardiovascular and renal disease following hospitalization for acute heart failure," said Nile CEO Joshua Kazam.
- read the Nile release on the Medtronic pact
- and the other release about the drug itself